Since inception CereVasc has aggressively pursued patent protection in the United States and abroad for the endovascular treatment of communicating hydrocephalus. To date, the eShunt System development project has generated several issued US patents and additional applications pending in the US and abroad. The Company also has exclusive rights to the original endovascular CSF shunt patent rights and all improvements through a license with Tufts Medical Center, Inc.
Partner with us:
CereVasc is actively seeking pharma and biotechnology partners who desire a novel approach to delivering their CNS therapies.
For more information, contact us.